DEF: Cyanotech Corporation Schedules 2025 Annual Meeting Amidst Continued Losses and Executive Compensation Adjustments

Cyanotech Corporation has announced its 2025 Annual Meeting of Stockholders to address director elections, auditor ratification, and executive compensation frequency, while reporting ongoing net losses and negative shareholder returns.

Summary

• Cyanotech Corporation will hold its 2025 Annual Meeting of Stockholders on Thursday, August 21, 2025, at 2:00 P.M. Pacific Time, at the Nutrex Hawaii Warehouse in Rancho Cucamonga, California.
• Stockholders of record as of June 27, 2025, are entitled to vote, with 7,232,217 shares of common stock outstanding on that date.
• Key proposals include the election of four director nominees (Matthew K. Custer, Michael A. Davis, David M. Mulder, and David L. Vied), the ratification of BPM LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026, and an advisory vote on the frequency of future advisory votes on Named Executive Officer compensation, with the Board recommending a three-year frequency.
• The company reported a net loss of $3,203,000 for fiscal year 2025, following losses of $5,267,000 in fiscal year 2024 and $3,440,000 in fiscal year 2023.
• Total Shareholder Return (TSR) for an initial $100 investment was $11 for fiscal year 2025, $9 for fiscal year 2024, and $27 for fiscal year 2023, indicating significant value erosion.
• No bonus incentive compensation was accrued or paid to Named Executive Officers for fiscal year 2025 performance due to the company's lack of profitability.
• As of March 31, 2025, the company had $1,000,000 outstanding on a related party note and $3,000,000 outstanding on a revolving line of credit from an entity affiliated with Board Chairman Michael A. Davis.
• Matthew K. Custer's Executive Employment Agreement was renewed effective June 16, 2025, setting his annual base salary at $200,000 in cash and $25,000 in Restricted Stock Units (RSUs), along with a $25,000 signing bonus and 150,000 stock options.
• Jennifer C. Rogerson was appointed Chief Financial Officer in September 2024, succeeding Felicia Ladin.
• The Board of Directors met formally four times in fiscal year 2025, with all directors attending 100% of Board and committee meetings.
• The company maintains a separation of the Chief Executive Officer and Board Chairman positions as a matter of good corporate governance.

Sentiment

Score: 3

Explanation: The company continues to report significant net losses and negative shareholder returns over multiple fiscal years, indicating ongoing financial challenges. While corporate governance practices appear sound, the core financial performance is a strong negative.

Positives

• The company maintains strong corporate governance practices, including the separation of CEO and Board Chairman roles, independent directors, and active audit, nominating, and compensation committees.
• All directors demonstrated full attendance at Board and committee meetings during fiscal year 2025, indicating strong engagement.
• The Board and management team possess extensive experience in the food, supplement, and micro-algae industries, with key executives having long tenures and specialized expertise.
• The company has an ongoing commitment to good governance, regularly monitoring and balancing processes in light of new best practices and regulatory changes.
• The equity incentive program is designed to align management and employee interests with long-term shareholder goals, fostering an ownership ethic.

Negatives

• The company reported consistent net losses for three consecutive fiscal years: $(3,440) thousand in FY2023, $(5,267) thousand in FY2024, and $(3,203) thousand in FY2025.
• Total Shareholder Return (TSR) has been significantly negative, with an initial $100 investment declining to $27 by FY2023, $9 by FY2024, and $11 by FY2025.
• Named Executive Officers did not receive bonus incentive compensation for fiscal year 2025 performance due to the company's lack of profitability.
• The company relies on a related party loan and revolving line of credit from an entity affiliated with the Board Chairman, with $4,000,000 outstanding as of March 31, 2025.

Risks

• Financial risks related to the company's ongoing net losses and ability to achieve sustainable profitability.
• Risks associated with the company's financial reporting process, financial statements, and internal controls, which are overseen by the Audit Committee.
• Risks related to the Board's organization, membership, governance, and structure, managed by the Nominating and Corporate Governance Committee.
• Risks arising from the company's compensation policies, bonus plans, and incentive equity plans, overseen by the Compensation Committee.
• Cybersecurity risks, which the Board considers critical and oversees management's risk management program.
• Dependence on related party financing, including a $1,000,000 note and a $3,000,000 revolving line of credit, which mature in April 2027 and April 2026, respectively.

Future Outlook

The Board believes that holding advisory votes on executive compensation every three years is most consistent with the company's approach to enhancing long-term growth and attracting, retaining, and motivating executive officers over the long term. The company expects to make equity award grants annually under the 2016 Plan and grant Restricted Stock Units (RSUs) every three years to all employees to foster an ownership ethic and align interests with the company's long-term future.

Management Comments

• "Your vote is important. Whether or not you plan to attend the Annual Meeting, please vote your shares."
• "Management does not know of any other matters to be presented at the Annual Meeting other than those set forth in this Proxy Statement and in the Notice accompanying this Proxy Statement."
• "The Board presently believes that future say-on-pay votes should occur every three years."
• "The Board believes that holding a say-on-pay vote every three years is most consistent with the Company’s approach to executive compensation in which the Company seeks to enhance the long-term growth of the Company and to attract, retain and motivate our executive officers over the long term."

Industry Context

Cyanotech Corporation operates within the natural and organic foods, nutraceuticals, and agriculture sectors, specializing in micro-algae production, including Astaxanthin. The company's focus on long-term growth and attracting talent aligns with broader industry trends emphasizing innovation and specialized product development in the health and wellness market.

Comparison to Industry Standards

• Executive compensation is determined based on salary surveys conducted by third parties or the company's Vice President of Human Resources, targeting the median for comparably sized companies in the Hawaii and California markets.
• The company's independent directors meet the independence requirements under Section 1.1(9) of the OTCQB Listing Rules.
• The Audit Committee Chairman, David M. Mulder, meets the requirements of an audit committee financial expert as defined in Item 407(d)(5) of Regulation S-K.

Management Changes

Corporate Governance

Related Party Transactions

• In April 2019, the company obtained a loan of $1,500,000 from an entity affiliated with Michael A. Davis, the Chairman of the Board.
• This loan was amended on April 12, 2021, December 14, 2022, August 14, 2023, and August 9, 2024, to include a revolving line of credit up to $4,000,000.
• As of March 31, 2025, $1,000,000 was outstanding on the related party note and $3,000,000 was outstanding on the revolving line of credit.
• The loan matures on April 12, 2027, and the revolving line of credit matures on April 12, 2026.

Stakeholder Impact

• Shareholders: Will vote on key governance matters (director elections, auditor, say-on-pay frequency), are impacted by negative Total Shareholder Return, and have their interests aligned with management through equity awards. The related party debt could be a concern.
• Employees: Benefit from equity awards (RSUs every three years) and are subject to compensation policies, with bonuses tied to company profitability.
• Management: Compensation is structured with base salary, potential bonuses (contingent on profitability), and equity awards. Employment agreements for key executives provide stability and incentives.
• Creditors: The related party loan and revolving line of credit represent significant financial obligations to an affiliated entity.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on August 21, 2025, to vote on director elections, auditor ratification, and the frequency of future say-on-pay votes.
• The Board will consider the outcome of the advisory vote on say-on-pay frequency when making future decisions.
• The company expects to make annual equity award grants under the 2016 Plan to select executives and key employees.
• The company expects to grant Restricted Stock Units (RSUs) every three years to all employees.
• Stockholders wishing to present proposals for the 2026 Annual Meeting must submit them by March 12, 2026 (Rule 14a-8) or between March 24, 2026, and April 23, 2026 (Bylaws).

Key Dates

Keywords

Cyanotech Corporation, Proxy Statement, SEC Filing, Annual Meeting, Corporate Governance, Executive Compensation, Board of Directors, Financial Performance, Net Loss, Shareholder Return, Auditor Ratification, Say-on-Pay, Equity Awards, Related Party Transactions, Nutraceuticals, Micro-algae, Astaxanthin, Spirulina